CENTOGENE News & Events Header Image Broschure

News

Stay up to date and read about our most recent milestones towards achieving CENTOGENE’s mission: To enable the cure of 100 rare diseases in 10 years.

Interested in receiving the latest news around the clock? Follow us on LinkedIn.

  • Enables refocusing on core business of delivering valuable, data-driven insights to patients, and pharmaceutical companies globally
  • EUR 15 million…

Dr. Andrin Oswald resigns as CEO due to prolonged medical leave; Kim Stratton elected as successor

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN,…

  • CENTOGENE and Insilico Medicine will work together to identify, rank, and annotate proteins to identify novel therapeutic targets for NPC using AI
  • The CentoCloud solution is a cloud-based Software as a Service (SaaS) platform that enables laboratories around the world to analyze, interpret, and…

Leveraging AI to Accelerate the Path From Diagnosis to Cure

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, December 20, 2021 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), a commercial-stage company…

Second Consecutive Quarter of Core Business Growth, Phasing Out COVID-19 Testing and Restructuring Organization for Core Rare Disease Business

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, November 18, 2021 (GLOBE NEWSWIRE) - Centogene N.V. (Nasdaq: CNTG), a commercial-stage company…

Providing Global Clinical Trial Support for Thalassemia and Sickle Cell Disease Will Deepen Understanding of Disease Characterization in the Search…

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, October 28, 2021 (GLOBE NEWSWIRE

  • FTD is a rapidly progressing neurodegenerative disease; up to…

For Further Inquiries Please Contact

Press Contact

Ben Legg

Corporate Communications

Email Us

Downloads

Here you can find forms, brochures, flyer and information sheets for download (PDF) about the broad genetic testing product and service portfolio of CENTOGENE.

Downloads